Introduction
HER2 gene amplification occurs in 20-25% of breast cancers and is associated with high relapse and poor prognosis rates (Bose et al., 2013; Slamon et al., 1987; Yarden and Pines, 2012) . Trastuzumab (Herceptin) is a monoclonal antibody that inhibits downstream signaling of intracellular transduction by targeting the extracellular domain of the HER2 gene. Although trastuzumab is effective, the efficiency is only approximately 26%, even in HER2-overexpressing breast cancer patients. The median remission is approximately 9 months, and the majority of patients acquire resistance to trastuzumab within 1 year (Rexer et al., 2013; Walsh et al., 2013) . In combination with another HER2-targeted drug Lapatinib, a tyrosinase inhibitor, the treatment remains ineffective in approximately half of patients.
Trastuzumab therapy may increase the risk of brain metastases in some patients with breast cancer (Cortes et al., 2015; Del Mastro et al., 2012) .
Trastuzumab treatment costs approximately US$45,000 a year in China, which is an enormous financial burden to families of breast cancer patients (Shiroiwa et al., 2008) . To overcome resistance and improve the efficacy of trastuzumab treatment in HER2-overexpressing breast cancer patients, we must perform a thorough inquiry into the mechanisms of trastuzumab resistance and develop new effective treatment programs.
A variety of potential molecular mechanisms of resistance to trastuzumab have previously been published (Berns et al., 2007; Nagata et al., 2004; Reim et al., 2009; Zhang et al., 2011) , and the vast majority involve the biological functions of breast cancer stem cells (BCSCs) (Castagnoli et al., 2016; Reim et al., 2009) . Cancer stem cells (CSCs) are a rare fraction of tumor cells that have the abilities of self-renewal, unlimited proliferation and multi-potent differentiation (Dalerba and Clarke, 2007) . Like normal tissues, tumor tissues are composed of a variety of heterogeneous tumor cells and originate from corresponding stem cells. CSCs have been isolated from a variety of tumors, such as leukemia, lung cancer, and breast cancer (Dietrich et al., 2014; Ho et al., 2007; Marotta et al., 2011) . There are two recognized methods of separating BCSCs from breast cancer patients and cell lines: one is surface phenotypic marker screening, and the other is Hoechst 33342 dye exclusion.
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-is a well-known surface maker for the isolation and identification of BCSCs in breast cancer tissues and cell lines (Al-Hajj et al., 2003; Marotta et al., 2011) .
There is mounting evidence that CSCs are responsible for tumor formation, infinite growth, recurrence and metastasis. CSCs have congenital resistance features. Conventional drug therapy, including chemotherapy drugs, radiotherapy drugs and targeted therapy drugs, can kill only the active non-stem cells, whereas residual CSCs can eventually lead to tumor recurrence and metastasis. CSCs are the root cause of drug resistance and treatment failure (Hong et al., 2009; Lemoli et al., 2009 ). The mechanisms of drug resistance in CSCs include overexpression of ATP-binding cassette transporters, over-activation of cell detoxification enzymes, abnormal activation of cell survival and apoptosis-related signal transduction pathways, the protective effect of tumor niches on tumor stem cells, and that most CSCs are in a quiescent phase (Bardelli and Siena, 2010; Gottesman, 2002; Lin et al., 2010) . By intervening in these processes, we may reverse resistance to trastuzumab and improve the survival and prognosis of breast cancer patients.
MicroRNAs ( CSCs and enhances their sensitivity to drugs (Tanaka et al., 2009; Yoo et al., 2011 ).
In addition, Jagged1, ZEB1 and Bmi1 are highly critical genes in these three signaling pathways. They are the direct target genes of the miR-200 family in many cancers, including breast cancer (Korpal et al., 2008; Liu et al., 2014; Vallejo et al., 2011) . Based on the above, BCSCs are the key factor responsible for trastuzumab resistance in HER2-overexpressing breast cancer.
miR-200c may suppress stemness and increase the sensitivity to trastuzumab in HER2+ breast cancer cells and stem cells. The study of the mechanism may be helpful for targeting BCSCs that are not successfully killed by trastuzumab and may improve the survival and prognosis of HER2-overexpressing breast cancer patients.
Materials and Methods
Clinical samples
All human breast cancer tumor samples were obtained from randomly selected cancer patients at the Sun Yat-Sen University Cancer Center (SYSUCC), Guangzhou, China. The diagnoses of breast cancer were pathologically confirmed in all cases. The patients had not received any prior chemotherapy. Tissue samples were collected intraoperatively. Written informed consent was obtained from all eligible patients who participated in the study before or after surgery, and all protocols were reviewed and approved by the Joint Ethics Committee of SYSUCC and used according to the ethical standards as formulated in the Helsinki Declaration.
Adherent cell and tumor sphere culture
All adherent breast cancer cell lines used in this study were purchased were grown in DMEM/F12 supplemented with 1% B27, EGF (20 ng/ml), basic fibroblast growth factor (bFGF) (10 ng/ml), and insulin (10 mg/ml) (Invitrogen).
The spheres were counted and collected 5 days after being planted. They were mechanically dissociated with a 25 G needle (BD) and reseeded in fresh medium.
Mammosphere formation assay
Cells were plated in 6-well plates for 24 h and transfected. After incubation for 48 h, cells were harvested and plated at 10 4 cells/well in ultra-low-attachment six-well plates in serum-free DMEM/F12 supplemented with B27 (1:50), EGF (20 ng/ml), bFGF (10 ng/ml) and insulin (10 mg/ml).
Mammospheres were counted after 5 days of culture using a Nikon Eclipse TE2000-S microscope (Japan) and photographed with Meta Morph.
Transient and stable overexpression of miR-200c
Recombinant lentivirus vectors encoding miR-200c (miR-200c) of polybrene (4 mg/ml) and selected with puromycin (1 mg/ml).
RNA extract and qRT-PCR
Total RNA from cells was extracted with TRIzol reagent (Invitrogen) following the manufacturer's protocol. Reverse transcription and quantitative real-time PCR analysis (qRT-PCR) reactions were performed using a qSYBR-Green-containing PCR kit (Qiagen, Germantown, USA) and a BioRad IQTM5 Multicolor Real-Time PCR Detection System (USA). The primers for Jagged1, ZEB1 and Bmi1 mRNA for qRT-PCR detection were synthesized by
Invitrogen. Each experiment was performed three times in triplicate.
Protein isolation and western blotting
Protein was extracted from cells lines using RIPA lysis buffer with proteinase inhibitors (Thermo, Rockford, USA). The Protein BCA Assay Kit (Thermo) was used to measure the concentration of protein in the lysates.
Each lane was loaded with 20 µg protein mixed with 2× SDS loading buffer (Thermo). The protein was separated by 12% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes (Millipore, Bedford, USA). The membranes were incubated with 5% skim milk powder at room temperature for 1 h to block nonspecific binding. Subsequently, the membranes were incubated with antiserum containing antibodies against Jagged1, ZEB1 and Bmi1 (CST, Massachusetts, USA), at 4°C for 12 h. To visualize the target proteins, a 1:5000 dilution of peroxidase-conjugated secondary antibody and ECL western blotting detection reagents (GE, USA)
were used. A Bio Image Intelligent Quantifier 1-D was used to quantify the proteins (Version 2.2.1, Nihon-BioImage Ltd., Japan). An anti-GAPDH antibody was used as a protein loading control (Boster, Wuhan, China).
MTT assay
Cell viability analysis was preformed according to the methods using 3-(4, 5-dimethylthiazol)-2, 5-diphenyltetrazolium bromide (Tang et al., 2011) . SKBR3
and SKBR3-S cells were divided into mock (negative control), Trastuzumab 
Apoptosis rate determined by flow cytometry
SKBR3 and SKBR3-S were divided into five groups as in the MTT assay.
Cells at 5×10 5 cells/ml were inoculated into 6-well culture plates and incubated at 37ºC. After culture for 72 h, cells were collected after digestion with 0.25% trypsin, washed with PBS three times, and resuspended in 500 ml binding buffer (10 mM HEPES/NaOH, 140 mM NaCl, 2.5 mM CaCl 2 , PH 7.4).
FITC-labeled Annexin V (50 mg/ ml, 5 ml) and PI (50 mg/ml, 5 ml) were added, followed by incubation at room temperature in the dark for 30 min. The apoptosis rate was immediately measured by flow cytometry. Then, we selected HER2+ SKBR3 and HER2-MCF-7 cells for further study. All tissue samples in this study were collected from 50 breast cancer patients. The breast cancer tissues (Breast cancer) and their matched adjacent tissues (Normal) were removed during surgery and immediately stored in RNA later for RNA extraction and subsequent qRT-PCR assay.
Sort BCSCs by flow-cytometry
qRT-PCR results revealed that Jagged1, ZEB1 and Bmi1 mRNAs were upregulated in breast cancer tissues compared with matched adjacent tissues ( Figure 5A ).
Then, we explored the correlation between Jagged1, ZEB1 and Bmi1 expression using Pearson correlation analysis. The correlation coefficient between Jagged1 and ZEB1 was 0.731 (linear R2 = 0.534), between Jagged1
and Bmi1 was 0.362 (linear R2 = 0.131), and between ZEB1 and Bmi1 was 0.397 (linear R2 = 0.157), indicating that the expression levels of Jagged1 and ZEB1 were more strongly related than those of Jagged1 and Bmi1 or ZEB1
and Bmi1 (2-tailed, Figure 5B , 5C). In conclusion, these results are consistent with our hypothesis that miR-200c reduces stemness and increases sensitivity to trastuzumab in HER2+ breast cancer cells and stem cells via inhibition of Jagged1, ZEB1 and Bmi1, which are three important genes in the stemness-related Notch, Wnt and Hedgehog pathways. However, many molecular mechanisms remain unclear. We will continue to further explore the detailed molecular mechanisms and biological and pathological functions of miR-200c in increasing drug sensitivity to trastuzumab via these three pathways.
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